Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from CytoMed Therapeutics Limited ( (GDTC) ) is now available.
On October 14, 2025, CytoMed Therapeutics Limited announced a cash bid for the acquisition of potentially synergistic assets from TC BioPharm Limited, which entered administration on October 2, 2025. This acquisition aims to enhance CytoMed’s expertise in allogeneic cell therapies for cancer treatment, potentially accelerating its commercialization timeline and expanding its mission to provide affordable therapeutic options globally. This move represents CytoMed’s second acquisition in a year, following its purchase of a licensed cord blood bank in Malaysia in 2024, which supports its strategic expansion into new therapeutics.
The most recent analyst rating on (GDTC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.
Spark’s Take on GDTC Stock
According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.
GDTC’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and cash flow issues. Technical analysis provides some stability, but valuation remains unattractive due to ongoing losses and no dividend yield.
To see Spark’s full report on GDTC stock, click here.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company that focuses on developing novel affordable donor-derived cell-based immunotherapies for treating a wide range of cancers, including both blood and solid tumors. The company utilizes its proprietary technologies, such as gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create allogeneic immunotherapies. CytoMed was incorporated in 2018, spun off from Singapore’s Agency for Science, Technology and Research (A*STAR).
Average Trading Volume: 17,392
Technical Sentiment Signal: Hold
Current Market Cap: $24.17M
See more data about GDTC stock on TipRanks’ Stock Analysis page.